An ultraviolet‐curable, core–shell vaccine formed via phase separation. Issue 10 (6th June 2019)

• Record Type: Journal Article
• Authors: Lee, Jihui; Arun Kumar, Shreedevi; Souery, Whitney N.; Hinsdale, Taylor; Maitland, Kristen C.; Bishop, Corey J.
• Is Part Of: Journal of biomedical materials research. Volume 107:Issue 10(2019)
• Page Start: 2160
• Page End: 2173
• Publication Date: 2019-06-06
• Subjects: burst release -- HIV -- injectable polymer depot -- polybubble -- single‐injection vaccine; Biomedical materials -- Periodicals; 610.28
• DOI: 10.1002/jbm.a.36726
• Languages: English
• ISSNs: 1549-3296

Abstract

Abstract: One of the central challenges in the field of vaccine delivery is to develop a delivery method that maintains antigen stability while also enabling control over the system's release kinetics. Addressing these challenges would not only allow for expanded access to vaccines worldwide but would also help significantly reduce mortality rates in developing countries. In this article, we report the development of single‐injection vaccine depots for achieving novel delayed burst release. Synthesized poly(ε‐caprolactone) and poly(ε‐caprolactone) triacrylate were used to form stationary bubbles within an aqueous solution of 10% carboxymethylcellulose. These polymeric bubbles (referred to as "polybubbles") can then be injected with an aqueous solution of cargo, resulting in the formation of a polymeric shell. The puncture resulting from cargo injection self‐heals prior to ultraviolet (UV) curing. UV curing and lyophilization were shown to enhance the stability of the polybubbles. BSA‐ CF 488 and HIV1 gp120/41 were used as the antigen in the study as a proof‐of‐concept. Further endeavors to automate the production of polybubbles are underway.